This is the third competing continuation application for the Cancer Center Support Grant at Vanderbilt lngram Cancer Center (VICC). VICC is a matrix center within Vanderbilt University Medical Center (VUMC) that integrates the cancer-related expertise and resources of the Schools of Medicine, Nursing, Arts and Sciences, Engineering;Peabody School of Education and the fully integrated Veterans Administration Medical Center. Most facilities are located on one campus, which promotes interactions, sharing of resources, and collaborations. Established in 1993, VICC functions as an organizational unit with a supra-departmental status. VICC-specific authorities and responsibilities are: 1) to conduct, coordinate and integrate cancer-related activities of Vanderbilt University;2) to carry out, support and enhance cancer research throughout the University;3) to develop, manage, and provide cancer education programs;and 4) to coordinate and integrate the care of cancer patients at VUMC. The research objectives are accomplished through seven research programs, two of which evolved out of previous programs and are considered new since the previous application. The programs are: Host-Tumor Interactions, Signal Transduction and Cell Proliferation, Genome Maintenance (new), Gastrointestinal Cancer, Thoracic/Head &Neck Cancer (new), Breast Cancer, and Cancer Epidemiology, Prevention and Control. Thirteen shared resources are proposed, 11 previously supported and two new. There has been remarkable VICC growth and accomplishments over the past project period. VICC has been awarded 11 new multi-investigator and six new training grants. In addition, we successfully renewed all three NCI SPOREs as well as eight multi-investigator and 11 training grants. With these and many other NCI grants, we increased our NCI funding by 62%. Significant investments have been made in cancer drug discovery, personalized cancer medicine, cancer epidemiology prevention and control, genomics, proteomics, informatics, bioinformatics, diversity initiatives, and cancer health disparities. Increased VICC space and facilities, along with philanthropic and institutional funds, supported the recruitment of 66 new faculty, who join a dedicated team carrying out the VICC mission: to alleviate cancer death and suffering through pioneering research, innovative clinical trials, evidence-based patient-care, prevention, education, and community activities.

Public Health Relevance

The Vanderbilt-lngram Cancer Center Support Grant provides the infrastructure support to facilitate basic, clinical and population-based research relevant to our mission to alleviate cancer death and suffering through pioneering research, innovative patient care, evidence-based prevention, education and communication. Our vision is to be a preeminent cancer center in the Southeast and a recognized leader, nationally and globally in the effort to prevent and treat cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-16
Application #
8327676
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-17
Project End
2015-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
16
Fiscal Year
2012
Total Cost
$5,898,750
Indirect Cost
$2,117,500
Name
Vanderbilt University Medical Center
Department
Biochemistry
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Pannala, Venkat R; Wall, Martha L; Estes, Shanea K et al. (2018) Metabolic network-based predictions of toxicant-induced metabolite changes in the laboratory rat. Sci Rep 8:11678
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Doxie, Deon B; Greenplate, Allison R; Gandelman, Jocelyn S et al. (2018) BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. Pigment Cell Melanoma Res 31:708-719
Salisbury-Ruf, Christi T; Bertram, Clinton C; Vergeade, Aurelia et al. (2018) Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study. Elife 7:
Laroumanie, Fanny; Korneva, Arina; Bersi, Matthew R et al. (2018) LNK deficiency promotes acute aortic dissection and rupture. JCI Insight 3:
Burns, Michael C; Howes, Jennifer E; Sun, Qi et al. (2018) High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Anal Biochem 548:44-52
Phelps, Hannah M; Al-Jadiry, Mazin F; Corbitt, Natasha M et al. (2018) Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq. World J Pediatr 14:585-593
Liu, Qi; Herring, Charles A; Sheng, Quanhu et al. (2018) Quantitative assessment of cell population diversity in single-cell landscapes. PLoS Biol 16:e2006687
Almodovar, Karinna; Iams, Wade T; Meador, Catherine B et al. (2018) Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. J Thorac Oncol 13:112-123

Showing the most recent 10 out of 2462 publications